Strategies to protect surfactant and enhance its activity
Authors:
Open Access
- 1 December 2021
- journal article
- review article
- Published by Elsevier in Biomedical Journal
- Vol. 44 (6) , 654-662
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infantsCritical Care, 2013
- Ex Vivo Effect of Varespladib on Secretory Phospholipase A2 Alveolar Activity in Infants with ARDSPLOS ONE, 2012
- Surfactant protein B inhibits secretory phospholipase A2hydrolysis of surfactant phospholipidsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome*Critical Care Medicine, 2011
- Effect of Cholesterol on the Biophysical and Physiological Properties of a Clinical Pulmonary SurfactantBiophysical Journal, 2007
- Nonventilatory Treatments for Acute Lung Injury and ARDSChest, 2007
- Clara cell secretory protein and phospholipase A2activity modulate acute ventilator-induced lung injury in miceJournal of Applied Physiology, 2005
- Acute Respiratory Distress SyndromeDrugs, 2001
- Transfusion-related acute lung injury treated with surfactant in a neonateEuropean Journal of Pediatrics, 1996
- Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injuryEuropean Respiratory Journal, 1995